Endonovo Therapeutics Inc Net Income per Employee (ENDV), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Endonovo Therapeutics Inc   (ENDV)
 

Endonovo Therapeutics Inc Net Income per Employee

ENDV's Quarterly Results, Trends, Rankings, Statistics
Endonovo Therapeutics Inc recorded a cumulative net loss of $-4 million during 12 month ending in the third quarter 2023.
The Healthcare sector has seen employees of 180 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3901, from total ranking in previous quarter at 3948.


What is Income per Employee Ratio?






ENDV Net Income per Employee (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -440,414 -424,133 -883,112 -1,847,484 -314,637
ENDV's Total Ranking # 3901 # 3948 # 4337 # 5134 # 3864
Seq. Net Income Change - -71.46 % - - -


ENDV Net Income per Employee Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 181
Healthcare Sector # 514
Overall Market # 3901

Net Income per Employee Statistics
High Average Low
$ 617,748 $ -555,836 $ -1,847,484
(Mar 31 2015)   (Dec 31 2022)







Companies with similar Income per Employee for 12 month ending Sep 30 2023, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2023Number of Employees Sep 30 2023


Date modified: 2026-06-22T20:36:52+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.